Unlock stock picks and a broker-level newsfeed that powers Wall Street.

HKSE - Delayed Quote HKD

GRAND PHARMA (0512.HK)

Compare
5.600
-0.200
(-3.45%)
At close: 4:08:01 PM GMT+8

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.
NameTitlePayExercisedYear Born
Dr. Weikun Tang Executive Chairman 3.01M -- 1986
Mr. Chao Zhou CEO & Executive Director 2.48M -- 1990
Mr. Guang Yang Executive Director 50k -- 1977
Ms. Chit Yee Lam Executive Director 17k -- 1966
Liu Hu Investor Relations Director -- -- --
Mr. Tin Chung Foo CPA (Aust.), HKICPA Company Secretary -- -- 1969
Mr. Xiaofeng Shi Chairman of Grand Pharm (China) -- -- 1967
Xiaojie Chen Vice President -- -- --

GRAND PHARMA

The Center
Units 3302 99 Queen’s Road
Central
Hong Kong
https://www.grandpharm.com
Sector: 
Healthcare
Full Time Employees: 
11,987

Description

Grand Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices, biotechnology and healthcare products, and pharmaceutical raw materials. The company offers respiratory, ophthalmology, cerebro-cardiovascular emergency, and biotechnology related products. It manufactures and sells pharmaceutical, taurine, agrochemicals, chemical medicine, and amino acid series products. In addition, the company provides bio-pesticides and additives; disposal surgical products; and Chinese medicine and health food products, as well as engages in the treatment of sewage. The company has a strategic cooperation agreement with the Eye Hospital of Wenzhou Medical University in the field of ophthalmic drug research and development. It operates in the People's Republic of China, the rest of Asia, the United States, Europe, and internationally. The company was formerly known as China Grand Pharmaceutical and Healthcare Holdings Limited. The company was incorporated in 1995 and is based in Central, Hong Kong.

Corporate Governance

GRAND PHARMA’s ISS Governance QualityScore as of April 1, 2025 is 4. The pillar scores are Audit: 8; Board: 1; Shareholder Rights: 8; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

March 12, 2025 at 2:54 PM UTC

GRAND PHARMA Earnings Date

Recent Events

April 14, 2025 at 12:00 AM UTC

Ex-Dividend Date

Related Tickers